By analysis of various immune components in tumor, we found that the combination treatment was sufficient to augment the infiltration of CD8+ T cells and CD4+ T cells into the tumors, indicating a robust T-cell mediated anti-tumor immunity (Fig. 6H–J). Here, CD8A is linked to neoplasm.